Disease criteria of systemic lupus erythematosus (SLE); the potential role of non-criteria autoantibodies

Kamen, 2014, 40 Tanaka, 2020, State-of-the-art treatment of systemic lupus erythematosus, Int. J. Rheum. Dis., 23, 465, 10.1111/1756-185X.13817 Kaul, 2016, Systemic lupus erythematosus, Nat. Rev. Dis. Prim., 2 Agmon-Levin, 2012, Systemic lupus erythematosus one disease or many?, Autoimmun. Rev., 11, 593, 10.1016/j.autrev.2011.10.020 Tan, 1982, The 1982 revised criteria for the classification of systemic lupus erythematosus, Arthritis Rheum., 25, 1271, 10.1002/art.1780251101 Hochberg, 1997, Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus, Arthritis Rheum., 40, 1725, 10.1002/art.1780400928 Petri, 2012, Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus, Arthritis Rheum., 64, 2677, 10.1002/art.34473 Aringer, 2019, European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus, Ann. Rheum. Dis., 78, 1151, 10.1136/annrheumdis-2018-214819 Aringer, 2019, European league against rheumatism/American college of rheumatology classification criteria for systemic lupus erythematosus, Arthritis Rheumatol., 71, 1400, 10.1002/art.40930 Aringer, 2019, European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus, Ann. Rheum. Dis., 78, 1151, 10.1136/annrheumdis-2018-214819 Aringer, 2016, Toward new criteria for systemic lupus erythematosus-a standpoint, Lupus, 25, 805, 10.1177/0961203316644338 Leuchten, 2018, Performance of antinuclear antibodies for classifying systemic lupus erythematosus: a systematic literature review and meta-regression of diagnostic data, Arthritis Care Res., 70, 428, 10.1002/acr.23292 Aringer, 2020, New criteria for lupus, Curr. Rheumatol. Rep., 22, 10.1007/s11926-020-00896-6 Irure-Ventura, 2021, Rare immunofluorescence patterns of autoantibodies on HEp-2 cells defined by ICAP identify different autoimmune diseases in the absence of associated specificities: a Spanish multicentre study, Rheumatology, 60, 3904, 10.1093/rheumatology/keaa831 Yaniv, 2015, A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients, Autoimmun. Rev., 14, 75, 10.1016/j.autrev.2014.10.003 Choi, 2019, Autoantibodies in SLE: prediction and the p value matrix, Lupus, 28, 1285, 10.1177/0961203319868531 Mohan, 1993, Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus, J. Exp. Med., 177, 1367, 10.1084/jem.177.5.1367 Mehra, 2014, The spectrum of anti-chromatin/nucleosome autoantibodies: independent and interdependent biomarkers of disease, J. Immunol. Res., 2014 Bruns, 2000 Ghillani-Dalbin, 2003, Testing for anti-nucleosome antibodies in daily practice: a monocentric evaluation in 1696 patients, Lupus, 12, 833, 10.1191/0961203303lu475oa Amoura, 1994, Nucleosome-restricted antibodies are detected before anti-dsDNA and/or antihistone antibodies in serum of MRL-Mp lpr/lpr and +/+ mice, and are present in kidney eluates of lupus mice with proteinuria, Arthritis Rheum., 37, 1684, 10.1002/art.1780371118 Kramers, 1994, Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo, J. Clin. Invest., 94, 568, 10.1172/JCI117371 Arbuckle, 2003, Development of autoantibodies before the clinical onset of systemic lupus erythematosus, N. Engl. J. Med., 349, 1526, 10.1056/NEJMoa021933 Mohan, 1993, Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus, J. Exp. Med., 177, 1367, 10.1084/jem.177.5.1367 Simón, 2004, Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker, Rheumatology, 43, 220, 10.1093/rheumatology/keh024 Amoura, 2000, The role of nucleosomes in lupus, Curr. Opin. Rheumatol., 12, 369, 10.1097/00002281-200009000-00003 Augusto Gutiérrez-Adrianzén, 2006 Suleiman, 2009, Anti-nucleosome antibodies as a disease activity marker in patients with systemic lupus erythematosus, Int. J. Rheum. Dis., 12, 100, 10.1111/j.1756-185X.2009.01391.x Gómez-Puerta, 2008, Anti-chromatin (anti-nucleosome) antibodies: diagnostic and clinical value, Autoimmun. Rev., 7, 606, 10.1016/j.autrev.2008.06.005 Bizzaro, 2012, Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis, Autoimmun. Rev., 12, 97, 10.1016/j.autrev.2012.07.002 Burlingame, 2004, Recent advances in understanding the clinical utility and underlying cause of antinucleosome (antichromatin) autoantibodies, Clin. Appl. Immunol. Rev., 5, 351, 10.1016/j.cair.2004.04.002 Saisoong, 2006, Correlations between antinucleosome antibodies and anti-double-stranded DNA antibodies, C3, C4, and clinical activity in lupus patients, Clin. Exp. Rheumatol., 24, 51 Li, 2015, Anti-nucleosome antibodies outperform traditional biomarkers as longitudinal indicators of disease activity in systemic lupus erythematosus, Rheumatology, 54, 449, 10.1093/rheumatology/keu326 Arinuma, 2008, Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus, Arthritis Rheum., 58, 1130, 10.1002/art.23399 Bigler, 2008, Antinucleosome antibodies as a marker of active proliferative lupus nephritis, Am. J. Kidney Dis. : Off. J. Nat. Kidney Found., 51, 624, 10.1053/j.ajkd.2007.10.041 Hung, 2011, Antinucleosome antibodies as a potential biomarker for the evaluation of renal pathological activity in patients with proliferative lupus nephritis, Lupus, 20, 1404, 10.1177/0961203311417033 Kiss, 2009, Anti-nuscleosome antibody, a reliable indicator for lupus nephritis, Autoimmunity, 42, 393, 10.1080/08916930903002446 Rekvig, 2014, Review: antinucleosome antibodies: a critical reflection on their specificities and diagnostic impact, Arthritis Rheumatol., 66, 1061, 10.1002/art.38365 Ghiggeri, 2019, An update on antibodies to necleosome components as biomarkers of sistemic lupus erythematosus and of lupus flares, Int. J. Mol. Sci., 20, 10.3390/ijms20225799 Sun, 2008, Anti-histones antibodies in systemic lupus erythematosus: prevalence and frequency in neuropsychiatric lupus, J. Clin. Lab. Anal., 22, 271, 10.1002/jcla.20248 Zamorano, 2010, [Drug-induced lupus], Med. Clínica, 135, 124 Zirwas, 2004, The utility of antihistone antibody screening in the diagnosis of drug-induced lupus erythematosus, Arch. Dermatol., 140, 494, 10.1001/archderm.140.4.494 Didier, 2018, Autoantibodies associated with connective tissue diseases: what meaning for clinicians?, Front. Immunol., 9, 541, 10.3389/fimmu.2018.00541 Rubin, 1995, IgG but not other classes of anti-[(H2A-H2B)-DNA] is an early sign of procainamide-induced lupus, J. Immunol., 154, 2483, 10.4049/jimmunol.154.5.2483 Borchers, 2007, Drug-induced lupus, Ann. N. Y. Acad. Sci., 1108, 166, 10.1196/annals.1422.019 Vaghela, 2019, Isoniazid-induced systemic lupus erythematosus: a case report, Drug Saf. Case Rep., 6, 10.1007/s40800-019-0102-y Salazar-Pdramo, 1992, Systemic lupus erythematosus induced by isoniazid, Ann. Rheum. Dis., 51, 1085, 10.1136/ard.51.9.1085 Yang, 2015, Co-positivity for anti-dsDNA, -nucleosome and -histone antibodies in lupus nephritis is indicative of high serum levels and severe nephropathy, PLoS One, 10 Cortés-Hernández, 2004, Antihistone and anti-double-stranded deoxyribonucleic acid antibodies are associated with renal disease in systemic lupus erythematosus, Am. J. Med., 116, 165, 10.1016/j.amjmed.2003.08.034 Hu, 2010, Primary biliary cirrhosis: what do autoantibodies tell us?, World J. Gastroenterol., 16, 3616, 10.3748/wjg.v16.i29.3616 Nunes, 2018, Prevalence of auto-antibodies associated to pulmonary arterial hypertension in scleroderma - a review, Autoimmun. Rev., 17, 1186, 10.1016/j.autrev.2018.06.009 Patel, 2008, The assembly of a spliceosomal small nuclear ribonucleoprotein particle, Nucleic Acids Res., 36, 6482, 10.1093/nar/gkn658 Migliorini, 2005, Anti-Sm and anti-RNP antibodies, Autoimmunity, 38, 47, 10.1080/08916930400022715 Dima, 2018, The impact of anti-U1-RNP positivity: systemic lupus erythematosus versus mixed connective tissue disease, Rheumatol. Int., 38, 1169, 10.1007/s00296-018-4059-4 Cozzani, 2014, Serology of lupus erythematosus: correlation between immunopathological features and clinical aspects, Autoimmune Dis., 10.1155/2014/321359 Mohammed Yousef, 2018, Association of anti-RNP with HLADR4 and its prevalence in rheumatoid arthritis patients, J. Immunoassay Immunochem., 39, 595, 10.1080/15321819.2018.1525396 Abbara, 2019, Anti-RNP positivity in primary Sjögren’s syndrome is associated with a more active disease and a more frequent muscular and pulmonary involvement, RMD Open, 5, 10.1136/rmdopen-2019-001033 Casal-Dominguez, 2019, Muscular and extramuscular features of myositis patients with anti-U1-RNP autoantibodies, Neurology, 92, E1416, 10.1212/WNL.0000000000007188 Coppo, 2002, Inflammatory myositis associated with anti-U1-small nuclear ribonucleoprotein antibodies: a subset of myositis associated with a favourable outcome, Rheumatology, 41, 1040, 10.1093/rheumatology/41.9.1040 Reichlin, 1986, Significance of the Ro antigen system, J. Clin. Immunol., 6, 339, 10.1007/BF00915372 Franceschini, 2005, Anti-Ro/SSA and La/SSB antibodies, Autoimmunity, 38, 55, 10.1080/08916930400022954 Chan, 1987, The small nuclear ribonucleoprotein SS-B/La binds RNA with a conserved protease-resistant domain of 28 kilodaltons, Mol. Cell Biol., 7, 2588 Harley, 1986, Anti-Ro (SS-A) and anti-La (SS-B) in patients with Sjögren’s syndrome, Arthritis Rheum., 29, 196, 10.1002/art.1780290207 Shiboski, 2016, American college of rheumatology/European league against rheumatism classification criteria for primary sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts, Arthritis Rheumatol., 69, 35 Robbins, 2019, Diagnostic utility of separate anti-ro60 and anti-ro52/TRIM21 antibody detection in autoimmune diseases, Front. Immunol., 10, 10.3389/fimmu.2019.00444 Zampeli, 2021, Anti-Ro52 and/or anti-Ro60 immune reactivity: autoantibody and disease associations, Clinical and Experimental Rheumatology, 38, S134 Izmirly, 2012, Neonatal lupus: advances in understanding pathogenesis and identifying treatments of cardiac disease, Curr. Opin. Rheumatol., 24, 466, 10.1097/BOR.0b013e328356226b Alexander, 1992, Anti-Ro/SS-A antibodies in the pathophysiology of congenital heart block in neonatal lupus syndrome, an experimental model. In vitro electrophysiologic and immunocytochemical studies, Arthritis Rheum., 35, 176, 10.1002/art.1780350209 de Carolis, 2020, Autoimmune congenital heart block: a review of biomarkers and management of pregnancy, Front. Pediat., 8, 10.3389/fped.2020.607515 Elkon, 1985, Lupus autoantibodies target ribosomal P proteins, J. Exp. Med., 162, 459, 10.1084/jem.162.2.459 Elkon, 1986, Identification and chemical synthesis of a ribosomal protein antigenic determinant in systemic lupus erythematosus, Proc. Natl. Acad. Sci. U. S. A., 83, 7419, 10.1073/pnas.83.19.7419 Yalaoui, 2002, Autoantibodies to ribosomal P proteins in systemic lupus erythematosus, Joint Bone Spine, 69, 173, 10.1016/S1297-319X(02)00366-4 Carmona-Fernandes, 2013, Anti-ribosomal P protein IgG autoantibodies in patients with systemic lupus erythematosus: diagnostic performance and clinical profile, BMC Med., 11, 10.1186/1741-7015-11-98 Arnett, 1996, Ribosomal P autoantibodies in systemic lupus erythematosus. Frequencies in different ethnic groups and clinical and immunogenetic associations, Arthritis Rheum., 39, 1833, 10.1002/art.1780391109 Mei, 2018, Clinical and serological associations of anti-ribosomal P0 protein antibodies in systemic lupus erythematosus, Clin. Rheumatol., 37, 703, 10.1007/s10067-017-3886-0 Kang, 2019, Protective role of anti-ribosomal P antibody in patients with lupus nephritis, Int. J. Rheum. Dis., 22, 913, 10.1111/1756-185X.13517 Mahler, 2004, Technical and clinical evaluation of anti-ribosomal P protein immunoassays, J. Clin. Lab. Anal., 18, 215, 10.1002/jcla.20026 Mahler, 2006, International multicenter evaluation of autoantibodies to ribosomal P proteins, Clin. Vaccine Immunol. : CVI, 13, 77, 10.1128/CVI.13.1.77-83.2006 Mahler, 2012, Multi-center evaluation of autoantibodies to the major ribosomal P C22 epitope, Rheumatol. Int., 32, 691, 10.1007/s00296-010-1685-x Mahler, 2008, Limited reliability of the indirect immunofluorescence technique for the detection of anti-Rib-P antibodies, Arthritis Res. Ther., 10, 10.1186/ar2548 Muro, 2009, Evaluation of anti-ribosomal P protein immunoassay in Japanese patients with connective tissue diseases: comparison with an indirect immunofluorescence assay, Scand. J. Rheumatol., 38, 460, 10.3109/03009740903008767 Damoiseaux, 2016, International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results, Auto Immun. Highlights, 7, 1, 10.1007/s13317-016-0075-0 Damoiseaux, 2019, Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective, Ann. Rheum. Dis., 78, 879, 10.1136/annrheumdis-2018-214436 Choi, 2019, Antinuclear antibody-negative systemic lupus erythematosus in an international inception cohort, Arthritis Care Res., 71, 893, 10.1002/acr.23712 Damoiseaux, 2005, Evaluation of a novel line-blot immunoassay for the detection of antibodies to extractable nuclear antigens, Ann. N. Y. Acad. Sci., 1050, 340, 10.1196/annals.1313.036 Mahler, 2003, Characterization of the human autoimmune response to the major C-terminal epitope of the ribosomal P proteins, J. Mol. Med. (Berl.), 81, 194, 10.1007/s00109-003-0423-1 Lin, 2005, Major immunoreactive domains of human ribosomal P proteins lie N-terminal to a homologous C-22 sequence: application to a novel ELISA for systemic lupus erythematosus, Clin. Exp. Immunol., 141, 155, 10.1111/j.1365-2249.2005.02816.x Agmon-Levin, 2009, Anti-ribosomal-P antibodies in lupus patients and healthy controls: evaluation of three ELISA assays, Isr. Med. Assoc. J., 11, 403 Fabien, 1999, Autoantibodies directed against the ribosomal P proteins are not only directed against a common epitope of the P0, P1 and P2 proteins, J. Autoimmun., 13, 103, 10.1006/jaut.1999.0291 Heinlen, 2010, Ribosomal P autoantibodies are present before SLE onset and are directed against non-C-terminal peptides, J. Mol. Med. (Berl.), 88, 719, 10.1007/s00109-010-0618-1 Zampieri, 2003, Recombinant anti-P protein autoantibodies isolated from a human autoimmune library: reactivity, specificity and epitope recognition, Cell. Mol. Life Sci. : CMLS, 60, 588, 10.1007/s000180300050 Haddouk, 2009, Clinical and diagnostic value of ribosomal P autoantibodies in systemic lupus erythematosus, Rheumatology, 48, 953, 10.1093/rheumatology/kep142 Olesińska, 2010, Clinical manifestation of systemic lupus erythematosus in patients with antiribosomal P protein antibodies, Pol. Arch. Med. Wewn., 120, 76 Barkhudarova, 2011, Diagnostic value and clinical laboratory associations of antibodies against recombinant ribosomal P0, P1 and P2 proteins and their native heterocomplex in a Caucasian cohort with systemic lupus erythematosus, Arthritis Res. Ther., 13, 10.1186/ar3244 Gerli, 2002, Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients, Rheumatology, 41, 1357, 10.1093/rheumatology/41.12.1357 Li, 2013, Significance of antibodies against the native ribosomal P protein complex and recombinant P0, P1, and P2 proteins in the diagnosis of Chinese patients with systemic lupus erythematosus, J. Clin. Lab. Anal., 27, 87, 10.1002/jcla.21543 Chindalore, 1998, The association between anti-ribosomal P antibodies and active nephritis in systemic lupus erythematosus, Clin. Immunol. Immunopathol., 87, 292, 10.1006/clin.1998.4541 Hirohata, 2011, Anti-ribosomal P antibodies and lupus nephritis, Clin. Exp. Nephrol., 15, 471, 10.1007/s10157-011-0462-9 Ghirardello, 2010, Anti-ribosomal P protein antibodies and neuropsychiatric systemic lupus erythematosus: cross-sectional vs. prospective studies, Lupus, 19, 771, 10.1177/0961203309353914 Hanly, 2011, Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus, Ann. Rheum. Dis., 70, 1726, 10.1136/ard.2010.148502 Pickering, 2000, Systemic lupus erythematosus, complement deficiency, and apoptosis, Adv. Immunol., 76, 227, 10.1016/S0065-2776(01)76021-X Leffler, 2014, The complement system in systemic lupus erythematosus: an update, Ann. Rheum. Dis., 73, 1601, 10.1136/annrheumdis-2014-205287 Schejbel, 2011, Molecular basis of hereditary C1q deficiency--revisited: identification of several novel disease-causing mutations, Gene Immun., 12, 626, 10.1038/gene.2011.39 Frémeaux-Bacchi, 1996, Autoantibodies to the collagen-like region of C1q are strongly associated with classical pathway-mediated hypocomplementemia in systemic lupus erythematosus, Lupus, 5, 216, 10.1177/096120339600500309 Siegert, 1991, IgG autoantibodies against C1q are correlated with nephritis, hypocomplementemia, and dsDNA antibodies in systemic lupus erythematosus, J. Rheumatol., 18, 230 Walport, 2002, Complement and systemic lupus erythematosus, Arthritis Res., 4, S279, 10.1186/ar586 Agnello, 1971, C1q precipitins in the sera of patients with systemic lupus erythematosus and other hypocomplementemic states: characterization of high and low molecular weight types, J. Exp. Med., 134, 228, 10.1084/jem.134.3.228 Antes, 1988, Evidence for the presence of autoantibodies to the collagen-like portion of C1q in systemic lupus erythematosus, Arthritis Rheum., 31, 457, 10.1002/art.1780310401 Uwatoko, 1988, Low-molecular weight C1q-binding immunoglobulin G in patients with systemic lupus erythematosus consists of autoantibodies to the collagen-like region of C1q, J. Clin. Invest., 82, 816, 10.1172/JCI113684 Wisnieski, 1992, IgG autoantibody to the collagen-like region of Clq in hypocomplementemic urticarial vasculitis syndrome, systemic lupus erythematosus, and 6 other musculoskeletal or rheumatic diseases, J. Rheumatol., 19, 884 Trendelenburg, 2006, High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis, Nephrol. Dial. Transplant. : Off. Publ. Eur. Dial. Trans. Assoc. Eur. Renal Assoc., 21, 3115, 10.1093/ndt/gfl436 Schaller, 2009, Autoantibodies against C1q in systemic lupus erythematosus are antigen-driven, J. Immunol., 183, 8225, 10.4049/jimmunol.0902642 Bock, 2015, Anti-C1q antibodies as a follow-up marker in SLE patients, PLoS One, 10, 10.1371/journal.pone.0123572 Meyer, 2009, Anti-C1q antibodies antedate patent active glomerulonephritis in patients with systemic lupus erythematosus, Arthritis Res. Ther., 11, 10.1186/ar2725 Matrat, 2011, Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: predictive value for renal flares, Lupus, 20, 28, 10.1177/0961203310379871 Mok, 2010, Performance of anti-C1q, antinucleosome, and anti-dsDNA antibodies for detecting concurrent disease activity of systemic lupus erythematosus, Transl. Res. : J. Lab. Clin. Med., 156, 320, 10.1016/j.trsl.2010.07.009 Julkunen, 2012, Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4, Rheumatol. Int., 32, 2445, 10.1007/s00296-011-1962-3 Akhter, 2011, Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers, Lupus, 20, 1267, 10.1177/0961203311411597 Csorba, 2021, Anti-C1q autoantibodies: standard quantification and innovative ELISA, Methods Mol. Biol., 2227, 107, 10.1007/978-1-0716-1016-9_10 Heidenreich, 2009, Sensitivity and specificity of autoantibody tests in the differential diagnosis of lupus nephritis, Lupus, 18, 1276, 10.1177/0961203309345753 Prada, 1992, IgG subclass restriction of autoantibody to solid-phase C1q in membranoproliferative and lupus glomerulonephritis, Clin. Immunol. Immunopathol., 63, 84, 10.1016/0090-1229(92)90097-8 Frémeaux-Bacchi, 1996, Autoantibodies to the collagen-like region of C1q are strongly associated with classical pathway-mediated hypocomplementemia in systemic lupus erythematosus, Lupus, 5, 216, 10.1177/096120339600500309 Trendelenburg, 2005, Antibodies against C1q in patients with systemic lupus erythematosus, Springer Semin. Immunopathol., 27, 276, 10.1007/s00281-005-0007-y Thanei, 2015, Anti-C1q autoantibodies from systemic lupus erythematosus patients activate the complement system via both the classical and lectin pathways, Clin. Immunol., 160, 180, 10.1016/j.clim.2015.06.014 Ramsey‐Goldman, 2021, A multianalyte assay panel with cell-bound complement activation products predicts transition of probable lupus to American college of rheumatology-classified lupus, ACR Open Rheumatol., 3, 116, 10.1002/acr2.11219 Mahler, 2010, Novel diagnostic and clinical aspects of anti-PCNA antibodies detected by novel detection methods, Lupus, 19, 1527, 10.1177/0961203310375265 Takasaki, 1984, Characterization of proliferating cell nuclear antigen recognized by autoantibodies in lupus sera, J. Exp. Med., 159, 981, 10.1084/jem.159.4.981 Kogure, 2002, Autoimmune responses to proliferating cell nuclear antigen multiprotein complexes involved in cell proliferation are strongly associated with their structure and biologic function in patients with systemic lupus erythematosus, Arthritis Rheum., 46, 2946, 10.1002/art.10606 Bravo, 1987, Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta, Nature, 326, 515, 10.1038/326515a0 Wenzel, 2000, Autoantibodies in patients with Lupus erythematosus: spectrum and frequencies, Dermatology (Basel, Switzerland), 201, 282, 10.1159/000018484 Fritzler, 1983, Clinical features of patients with antibodies directed against proliferating cell nuclear antigen, Arthritis Rheum., 26, 140, 10.1002/art.1780260204 Beyne-Rauzy, 2005, Anti-PCNA antibodies: prevalence and predictive value, Joint Bone Spine, 72, 432, 10.1016/j.jbspin.2004.11.005 Degiorgio, 2001, A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus, Nat. Med., 7, 1189, 10.1038/nm1101-1189 Ozawa, 1998, Glutamate receptors in the mammalian central nervous system, Prog. Neurobiol., 54, 581, 10.1016/S0301-0082(97)00085-3 Husebye, 2005, Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus, Ann. Rheum. Dis., 64, 1210, 10.1136/ard.2004.029280 Steup-Beekman, 2007, Anti-NMDA receptor autoantibodies in patients with systemic lupus erythematosus and their first-degree relatives, Lupus, 16, 329, 10.1177/0961203307078224 Hanly, 2004 Nasr, 2008, Necrotizing and crescentic lupus nephritis with antineutrophil cytoplasmic antibody seropositivity, Clin. J. Am. Soc. Nephrol. : CJASN., 3, 682, 10.2215/CJN.04391007 Pradhan, 2004, Anti-neutrophil cytoplasmic antibodies (ANCA) in systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies, J. Assoc. Phys. India, 52, 533 Pan, 2008, Anti-neutrophil cytoplasmic antibodies in new-onset systemic lupus erythematosus and lupus nephritis, Inflammation, 31, 260, 10.1007/s10753-008-9073-3 Pan, 2021, Perinuclear anti-neutrophil cytoplasmic antibody in systemic lupus erythematosus indicates more severe condition, Clin. Biochem., 89, 38, 10.1016/j.clinbiochem.2020.12.004 Jennette, 2006, Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies, J. Am. Soc. Nephrol. : JASN (J. Am. Soc. Nephrol.), 17, 1235, 10.1681/ASN.2005101048 Manolova, 2001, Antineutrophil cytoplasmic antibodies in patients with systemic lupus erythematosus: prevalence, antigen specificity, and clinical associations, Rheumatol. Int., 20, 197, 10.1007/s002960100108 Galeazzi, 1998, Anti-neutrophil cytoplasmic antibodies in 566 European patients with systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies. European Concerted Action on the Immunogenetics of SLE, Clin. Exp. Rheumatol., 16, 541 Moiseev, 2020, International consensus on ANCA testing beyond systemic vasculitis, Autoimmun. Rev., 19, 102618, 10.1016/j.autrev.2020.102618